ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Agilent Announces Thought Leader Award to David R. Liu at the Broad Institute

Researcher recognized for influential work on genome editing and CRISPR applications

Agilent Technologies Inc. (NYSE: A) today announced Dr. David R. Liu has been selected to receive a prestigious Agilent Thought Leader Award. A prominent researcher in the field of genome editing, Dr. Liu is Professor and Director of the Merkin Institute of Transformative Technologies in Healthcare, Vice-Chair of the Faculty at the Broad Institute of MIT and Harvard, Professor of Natural Sciences and Professor of Chemistry and Chemical Biology at Harvard University, and a Howard Hughes Medical Institute Investigator.

A primary direction of Dr. Liu's work has been a focus on using molecular editing tools such as CRISPR and developing the techniques of base editing and prime editing to study and address genetic diseases at their root cause: the genome. These tools enable targeted "rewriting" of the mutations responsible for the genetic disorders that affect hundreds of millions of people worldwide.

“I’m humbled and excited that our lab has been chosen for this award—a reflection of the creativity and dedication of our students and postdocs,” said Dr. Liu. “We can’t wait to try some new lines of research catalyzed by Agilent’s generous gift as well as their capabilities.”

“The research projects supported by this award will contribute to the continued expansion of CRISPR-based methods including prime and base editing,” said Kevin Meldrum, vice president and general manager of Agilent’s Genomics Division. “We look forward to applying our single guide RNA technology and suite of genomics profiling tools toward supporting the Liu lab’s innovative application of genome editing techniques.”

The Agilent Thought Leader Award program promotes fundamental scientific advances by contributing financial support, products, and expertise to the research of influential thought leaders in the life sciences, diagnostics, and chemical analysis space. To learn more, visit the Agilent Thought Leader Award web site.

About Agilent Technologies

Agilent is a leader in life sciences, diagnostics, and applied chemical markets, delivering innovative technology solutions that provide trusted answers to researchers’ most challenging scientific questions. The company generated revenue of $5.34 billion in fiscal year 2020 and employs 16,400 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, please subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn, Twitter, and Facebook.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  233.22
+0.00 (0.00%)
AAPL  278.85
+0.00 (0.00%)
AMD  217.53
+0.00 (0.00%)
BAC  53.65
+0.00 (0.00%)
GOOG  320.12
+0.00 (0.00%)
META  647.95
+0.00 (0.00%)
MSFT  492.01
+0.00 (0.00%)
NVDA  177.00
+0.00 (0.00%)
ORCL  201.95
+0.00 (0.00%)
TSLA  430.17
+0.00 (0.00%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.